Literature DB >> 24659153

[Recommendations for use of rituximab in patients with rheumatoid arthritis].

A Rubbert-Roth1, G R Burmester, T Dörner, A Gause.   

Abstract

Treatment with rituximab (RTX) has been approved since 2006 for patients with rheumatoid arthritis who previously failed to respond to tumor necrosis factor (TNF) inhibitor therapy or who experienced side effects. In these updated treatment recommendations new data relating to evaluation of the therapeutic response, retreatment, the role of predictive factors as well as safety data are incorporated and discussed.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24659153     DOI： 10.1007/s00393-013-1238-2

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


  56 in total

1.  Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis.

Authors:  Athina Pyrpasopoulou; Stella Douma; Themistoklis Vassiliadis; Sofia Chatzimichailidou; Areti Triantafyllou; Spyros Aslanidis
Journal:  Rheumatol Int       Date:  2009-10-15       Impact factor: 2.631

Review 2.  Monoclonal antibodies and progressive multifocal leukoencephalopathy.

Authors:  Daniel L Keene; Carole Legare; Elaine Taylor; Jim Gallivan; Gloria Mah Cawthorn; Duc Vu
Journal:  Can J Neurol Sci       Date:  2011-07       Impact factor: 2.104

3.  Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.

Authors:  Petra Roll; Arumugam Palanichamy; Christian Kneitz; Thomas Dorner; Hans-Peter Tony
Journal:  Arthritis Rheum       Date:  2006-08

4.  Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

Authors:  E Keystone; P Emery; C G Peterfy; P P Tak; S Cohen; M C Genovese; M Dougados; G R Burmester; M Greenwald; T K Kvien; S Williams; D Hagerty; M W Cravets; T Shaw
Journal:  Ann Rheum Dis       Date:  2008-04-03       Impact factor: 19.103

5.  Blood-borne human plasma cells in steady state are derived from mucosal immune responses.

Authors:  Henrik E Mei; Taketoshi Yoshida; Wondossen Sime; Falk Hiepe; Kathi Thiele; Rudolf A Manz; Andreas Radbruch; Thomas Dörner
Journal:  Blood       Date:  2008-11-05       Impact factor: 22.113

6.  Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders.

Authors:  Rogier M Thurlings; Koen Vos; Daniëlle M Gerlag; Paul P Tak
Journal:  Arthritis Rheum       Date:  2008-12

7.  Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.

Authors:  Y K O Teng; E W N Levarht; Rene E M Toes; Tom W J Huizinga; Jacob M van Laar
Journal:  Ann Rheum Dis       Date:  2008-07-22       Impact factor: 19.103

8.  Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients.

Authors:  M C Genovese; F C Breedveld; P Emery; S Cohen; E Keystone; E L Matteson; Y Baptiste; A Chai; L Burke; W Reiss; M Sweetser; T M Shaw
Journal:  Ann Rheum Dis       Date:  2009-01-20       Impact factor: 19.103

9.  Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

Authors:  Clifton O Bingham; R John Looney; Atul Deodhar; Neal Halsey; Maria Greenwald; Christine Codding; Benjamin Trzaskoma; Flavius Martin; Sunil Agarwal; Ariella Kelman
Journal:  Arthritis Rheum       Date:  2010-01

10.  Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.

Authors:  Paul Emery; Philip J Mease; Andrea Rubbert-Roth; Jeffrey R Curtis; Ulf Müller-Ladner; Norman B Gaylis; Sarah Williams; Mark Reynard; Helen Tyrrell
Journal:  Rheumatology (Oxford)       Date:  2011-09-16       Impact factor: 7.580
View more
  2 in total

Review 1.  [B cell therapy of rheumatoid arthritis with rituximab. Practice-relevant aspects for the routine].

Authors:  M Schmalzing; H-P Tony
Journal:  Z Rheumatol       Date:  2015-04       Impact factor: 1.372

2.  [Recommendations on the use of rituximab for ANCA-associated vasculitis].

Authors:  A M Gause; A Rubbert-Roth
Journal:  Z Rheumatol       Date:  2014-04       Impact factor: 1.372
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.